GlassScriptPhysician profile
Jacob Daniel Collins
NPI 1033690961
$23,383.56
in general payments reported to CMS, 2019-2025
37 companies · $10K in 2025
The $10K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,413 · 2022: $3,352 · 2023: $4,337 · 2024: $4,140 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $6,500 · Travel and Lodging: $1,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,987.27 |
| Consulting Fee | $6,500.00 |
| Travel and Lodging | $1,131.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $7,654.33 | 2021-2025 | Dovato, Apretude, Cabenuva |
| Pfizer INC. | $6,139.49 | 2023-2025 | |
| Gilead Sciences, INC. | $3,005.59 | 2021-2025 | Biktarvy |
| Emd Serono, INC. | $893.61 | 2021-2025 | Serostim |
| Biohaven Pharmaceuticals, INC. | $816.50 | 2021 | |
| Merck Sharp & Dohme LLC | $674.32 | 2021-2025 | Pifeltro, Delstrigo, Dificid |
| Napo Pharmaceuticals INC | $590.90 | 2022-2025 | Mytesi |
| Amgen INC. | $561.78 | 2022-2025 | Otezla, Repatha, Repatha |
| Bausch Health US, LLC | $463.81 | 2022-2025 | Aplenzin |
| Astrazeneca Pharmaceuticals LP | $309.18 | 2023-2025 | Breztri, Airsupra |
| Janssen Biotech, INC. | $295.87 | 2022-2023 | Symtuza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $293.26 | 2022-2024 | Xifaxan |
| Lilly USA, LLC | $243.91 | 2024-2025 | Zepbound, Mounjaro |
| Abbvie INC. | $163.85 | 2022-2025 | |
| Antares Pharma, INC. | $114.97 | 2021-2024 | Xyosted, Tlando, Nocdurna |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.